Improving Value for Lung & Breast Cancer: A European Pilot - PowerPoint PPT Presentation

Improving Value for Lung & Breast Cancer: A European Pilot Study of Outcomes Measurement Dr. Cláudia Vaz Business Development Manager, ICHOM c.vaz@ichom.org Rachel Tesfaye Program Manager, ICHOM r.Tesfaye@ichom.org Elizabeth Maclean Program Manager, ICHOM e.maclean@ichom.org All.Can is a multi-stakeholder initiative involving patient, clinical, academic and industry experts as well as policymakers. We aim to help define better solutions for sustainable cancer care and improve patient outcomes in the future. The All.Can initiative is made possible with financial support from Bristol-Myers Squibb (main sponsor), Amgen, MSD 1 and Johnson & Johnson (sponsors) and Varian (contributor), with additional non-financial support from IntaCare and GoingsOn.

Agenda Project rational and objectives Community and Timelines Impact All.Can is a multi-stakeholder initiative involving patient, clinical, academic and industry experts as well as policymakers. We aim to help define better solutions for sustainable cancer care and improve patient outcomes in the future. The All.Can initiative is made possible with financial support from Bristol-Myers Squibb (main sponsor), Amgen, MSD 2 and Johnson & Johnson (sponsors) and Varian (contributor), with additional non-financial support from IntaCare and GoingsOn.

ICHOM has delivered substantial success since launch All.Can is a multi-stakeholder initiative involving patient, clinical, academic and industry experts as well as policymakers. We aim to help define better solutions for sustainable cancer care and improve patient outcomes in the future. The All.Can initiative is made possible with financial support from Bristol-Myers Squibb (main sponsor), Amgen, MSD 3 and Johnson & Johnson (sponsors) and Varian (contributor), with additional non-financial support from IntaCare and GoingsOn.

The need for VBHC is widely recognized; ICHOM has been a driving force for VBHC All.Can is a multi-stakeholder initiative involving patient, clinical, academic and industry experts as well as policymakers. We aim to help define better solutions for sustainable cancer care and improve patient outcomes in the future. The All.Can initiative is made possible with financial support from Bristol-Myers Squibb (main sponsor), Amgen, MSD 4 and Johnson & Johnson (sponsors) and Varian (contributor), with additional non-financial support from IntaCare and GoingsOn.

ICHOM now wants to prove benefits of outcomes measurement through development of multi-stakeholder p rojects Principles of development of multi- stakeholder projects Focus on VBHC All.Can is a multi-stakeholder initiative involving patient, clinical, academic and industry experts as well as policymakers. We aim to help define better solutions for sustainable cancer care and improve patient outcomes in the future. The All.Can initiative is made possible with financial support from Bristol-Myers Squibb (main sponsor), Amgen, MSD 5 and Johnson & Johnson (sponsors) and Varian (contributor), with additional non-financial support from IntaCare and GoingsOn.

What Makes this Project Unique Standardized Measurement Creating Value Community ICHOM has forged an ICHOM is working collaboratively with international reputation in all healthcare stakeholders: patients, health outcomes measurement. professionals, payers and private The project is using ICHOM sector companies Standard Sets for lung cancer and breast cancer Actionable Data Patient Focused The outcomes collected will We start with patient insights. provide evidence for meaningful This is the basis of our research change. Results will impact all and objectives: improving healthcare stakeholders and have outcomes for patients the power to influence policy All.Can is a multi-stakeholder initiative involving patient, clinical, academic and industry experts as well as policymakers. We aim to help define better solutions for sustainable cancer care and improve patient outcomes in the future. The All.Can initiative is made possible with financial support from Bristol-Myers Squibb (main sponsor), Amgen, MSD 6 and Johnson & Johnson (sponsors) and Varian (contributor), with additional non-financial support from IntaCare and GoingsOn.

Create a community of healthcare providers, who will collaborate together to improve 1 cancer care 2 Measure outcomes consistently and in a standardised form Study objectives 3 Measure the costs of outcomes delivery via Time Driven Activity Based Costing. 4 Enable community members to benchmark their performance with one another 5 Measure patient perspectives/experiences regarding service inefficiency To codify an evidence base of value improvement strategies in lung and breast cancer 6 delivery. 7 Support the community in utilising cost and outcomes data to improve the efficiency and efficacy of their services. 8 To engage industry and governments in the learning from the programme. All.Can is a multi-stakeholder initiative involving patient, clinical, academic and industry experts as well as policymakers. We aim to help define better solutions for sustainable cancer care and improve patient outcomes in the future. The All.Can initiative is made possible with financial support from Bristol-Myers Squibb (main sponsor), Amgen, MSD 7 and Johnson & Johnson (sponsors) and Varian (contributor), with additional non-financial support from IntaCare and GoingsOn.

Centre Léon Bérard (Lyon) Hospital Juan Ramon Jimenez AZ Delta de Huelva Antwerp OLV University AALST Hospital (UZA) Instituto Português de Oncologia do Porto FG, EPE Basque Regional (IPO Porto) Service Osakidetza European - Donostia Provider Community Istituto Scientifico Romagnolo per lo Basque Regional Studio e la Cura dei Service Osakidetza Tumori-IRST (IRCCS) - Cruces Institut de Hospital Cancerologie de Universitario 12 l’Ouest (ICO) de Octubre University Hospital Basel All.Can is a multi-stakeholder initiative involving patient, clinical, academic and industry experts as well as policymakers. We aim to help define better solutions for sustainable cancer care and improve patient outcomes in the future. The All.Can initiative is made possible with financial support from Bristol-Myers Squibb (main sponsor), Amgen, MSD 8 and Johnson & Johnson (sponsors) and Varian (contributor), with additional non-financial support from IntaCare and GoingsOn.

Project timelines – high-level overview 6 months KEY 6 months Milestone achieved 9 months Milestone pending Outcomes Data collection ( Jan – Sept ‘19) 3b. Route-cause analysis (March - Oct) TDABC Mapping 3 months 2018 2019 2019 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec ESMO abstract TDABC Benchmarking report Launch submission Workshop Final data 9 th May meeting 20 th Sept Care Baseline data collection 18 th June 3-month follow- Patient pathway transfer TDABC report transfer up data transfer enrollment and mapping Reference Baseline data 15th Oct Guide Review collection begins Report on barriers & enablers July All.Can to data collection patient ICHOM 2019 ESMO survey results Conference Congress 7 th Feb 2 nd May 20th Oct Report on variation drivers All.Can is a multi-stakeholder initiative involving patient, clinical, academic and industry experts as well as policymakers. We aim to help define better solutions for sustainable cancer care and improve patient outcomes in the future. The All.Can initiative is made possible with financial support from Bristol-Myers Squibb (main sponsor), Amgen, MSD 9 and Johnson & Johnson (sponsors) and Varian (contributor), with additional non-financial support from IntaCare and GoingsOn.

1. PATIENTS PROVIDERS Hospitals can use the data to identify variations in 2. With real-time data collection, clinicians can use outcomes delivery. By identifying where they are PROMs results to better understand patients’ underperforming they can act to improve the effectiveness of their care. needs and improve their care. 3. Patients will feel more engaged and empowered Hospitals can use the TDABC mapping to identify in their healthcare journey. areas of inefficacy in their care. They can then redistribute resources to provide the right care at the right time, and the right cost INDUSTRY POLICY MAKERS Better understand the needs of patients, and the performance of providers. Use real-world evidence to better understand the effectiveness of care for different populations. Better understand the effect of treatment Inform value-based health care strategies such as modalities on outcomes beyond survival. bundled payments and outcomes based commissioning Improve the quality and cost-benefit of care Use evidence to advocate for improved patient care. All.Can is a multi-stakeholder initiative involving patient, clinical, academic and industry experts as well as policymakers. We aim to help define better solutions for sustainable cancer care and improve patient outcomes in the future. The All.Can initiative is made possible with financial support from Bristol-Myers Squibb (main sponsor), Amgen, MSD 10 and Johnson & Johnson (sponsors) and Varian (contributor), with additional non-financial support from IntaCare and GoingsOn.